N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice.
Animals
Brain Injuries, Traumatic
/ metabolism
Cerebral Cortex
/ metabolism
Conditioning, Classical
/ drug effects
Glycine
/ analogs & derivatives
Male
Mecamylamine
/ pharmacology
Mice
Nicotine
/ antagonists & inhibitors
Oleic Acids
/ antagonists & inhibitors
Oxazoles
/ pharmacology
PPAR alpha
/ agonists
Reward
Substance Withdrawal Syndrome
/ prevention & control
Tobacco Use Disorder
/ psychology
Tyrosine
/ analogs & derivatives
Cannabinoid receptor-1 (CB1)
Conditioned place preference (CPP)
Insular cortex
N-oleoyl glycine
Nicotine withdrawal
Peroxisome proliferator-activated receptor alpha (PPAR-α)
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
06
09
2017
revised:
01
03
2018
accepted:
17
03
2018
pubmed:
24
3
2018
medline:
28
12
2019
entrez:
24
3
2018
Statut:
ppublish
Résumé
Cigarette smokers with brain damage involving the insular cortex display cessation of tobacco smoking, suggesting that this region may contribute to nicotine addiction. In the present study, we speculated that molecules in the insular cortex that are sensitive to experimental traumatic brain injury (TBI) in mice might provide leads to ameliorate nicotine addiction. Using targeted lipidomics, we found that TBI elicited substantial increases of a largely uncharacterized lipid, N-acyl-glycine, N-oleoyl-glycine (OlGly), in the insular cortex of mice. We then evaluated whether intraperitoneal administration of OlGly would alter withdrawal responses in nicotine-dependent mice as well as the rewarding effects of nicotine, as assessed in the conditioned place preference paradigm (CPP). Systemic administration of OlGly reduced mecamylamine-precipitated withdrawal responses in nicotine-dependent mice and prevented nicotine CPP. However, OlGly did not affect morphine CPP, demonstrating a degree of selectivity. Our respective in vitro and in vivo observations that OlGly activated peroxisome proliferator-activated receptor alpha (PPAR-α) and the PPAR-α antagonist GW6471 prevented the OlGly-induced reduction of nicotine CPP in mice suggests that this lipid acts as a functional PPAR-α agonist to attenuate nicotine reward. These findings raise the possibility that the long chain fatty acid amide OlGly may possess efficacy in treating nicotine addiction.
Identifiants
pubmed: 29567093
pii: S0028-3908(18)30131-X
doi: 10.1016/j.neuropharm.2018.03.020
pmc: PMC6408981
mid: NIHMS1011962
pii:
doi:
Substances chimiques
GW 6471
0
N-oleoylglycine
0
Oleic Acids
0
Oxazoles
0
PPAR alpha
0
Tyrosine
42HK56048U
Mecamylamine
6EE945D3OK
Nicotine
6M3C89ZY6R
Glycine
TE7660XO1C
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
320-331Subventions
Organisme : NIDA NIH HHS
ID : P50 DA039841
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA033934
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007027
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA039942
Pays : United States
Organisme : CIHR
ID : 137122
Pays : Canada
Organisme : NIDA NIH HHS
ID : P01 DA009789
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA032246
Pays : United States
Informations de copyright
Copyright © 2018. Published by Elsevier Ltd.
Références
J Comput Chem. 2004 Jul 15;25(9):1157-74
pubmed: 15116359
Behav Brain Res. 2015 Sep 1;290:77-83
pubmed: 25934486
Biochem Pharmacol. 1995 Jun 29;50(1):83-90
pubmed: 7605349
Science. 1992 Dec 18;258(5090):1946-9
pubmed: 1470919
Eur J Pharmacol. 2003 Jun 27;471(3):185-93
pubmed: 12826237
J Pharmacol Exp Ther. 2008 Aug;326(2):483-92
pubmed: 18451315
Prostaglandins Other Lipid Mediat. 2006 Dec;81(3-4):136-49
pubmed: 17085322
Biochem Biophys Res Commun. 2015 Oct 23;466(3):438-43
pubmed: 26365347
Addict Biol. 2015 Jan;20(1):56-68
pubmed: 23869743
J Pharmacol Exp Ther. 2007 Jul;322(1):399-407
pubmed: 17446302
Addict Biol. 2013 Nov;18(6):930-6
pubmed: 22784230
Nutr Metab (Lond). 2011 Jul 13;8(1):51
pubmed: 21749725
Sleep. 2004 Aug 1;27(5):857-65
pubmed: 15453543
BMJ. 2004 Jun 26;328(7455):1519
pubmed: 15213107
J Cell Biochem. 2011 Nov;112(11):3227-33
pubmed: 21732409
Neuropsychopharmacology. 2015 Aug;40(9):2185-97
pubmed: 25754762
J Pharmacol Exp Ther. 2008 Apr;325(1):302-12
pubmed: 18184829
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Physiol Rev. 2009 Jan;89(1):73-120
pubmed: 19126755
Mol Pharmacol. 1988 Nov;34(5):605-13
pubmed: 2848184
Neuropharmacology. 2017 May 15;118:38-45
pubmed: 28279662
Neuropsychopharmacology. 2015 Dec;40(13):2948-59
pubmed: 26052038
Neuropsychopharmacology. 2013 Nov;38(12):2515-24
pubmed: 23817165
Nicotine Tob Res. 2016 Jan;18(1):74-8
pubmed: 25895948
J Pharmacol Exp Ther. 2001 Oct;299(1):332-42
pubmed: 11561096
Lipids. 2012 Apr;47(4):355-61
pubmed: 22160494
Ann N Y Acad Sci. 2014 May;1316:53-70
pubmed: 24690001
Pharmacol Biochem Behav. 2005 Jun;81(2):381-6
pubmed: 15925402
Neuroreport. 2004 Sep 15;15(13):2139-43
pubmed: 15486497
Brain Struct Funct. 2010 Jun;214(5-6):435-50
pubmed: 20512364
Science. 2007 Jan 26;315(5811):531-4
pubmed: 17255515
Behav Brain Res. 2013 Nov 1;256:273-8
pubmed: 23948214
Neuropsychopharmacology. 2013 Mar;38(4):690-8
pubmed: 23249816
Addict Biol. 2018 Jan;23(1):291-303
pubmed: 28429843
J Cereb Blood Flow Metab. 2011 Aug;31(8):1768-77
pubmed: 21505478
J Neurosci. 2013 Apr 3;33(14):6203-11
pubmed: 23554501
J Pharmacol Exp Ther. 1988 Dec;247(3):1046-51
pubmed: 2849657
J Chem Theory Comput. 2012 May 8;8(5):1542-1555
pubmed: 22582031
Neuropharmacology. 2002 Oct;43(5):857-67
pubmed: 12384171
Eur J Neurosci. 2010 Feb;31(4):733-41
pubmed: 20384816
J Med Chem. 2007 Dec 27;50(26):6554-69
pubmed: 18027904
Psychopharmacology (Berl). 2010 Jul;210(4):453-69
pubmed: 20414766
PLoS One. 2012;7(1):e29900
pubmed: 22291896
Front Psychiatry. 2015 Mar 25;6:41
pubmed: 25859226
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4810-5
pubmed: 9560184
Biol Psychiatry. 2010 Aug 1;68(3):265-71
pubmed: 20299008
Nicotine Tob Res. 2000 Feb;2(1):19-37
pubmed: 11072438
Neuropharmacology. 2016 Jun;105:308-317
pubmed: 26808314
Br J Pharmacol. 2002 Jan;135(2):564-78
pubmed: 11815392
Neuropharmacology. 2016 Nov;110(Pt A):251-259
pubmed: 27457507
Neuropsychopharmacology. 2012 Jul;37(8):1838-47
pubmed: 22453137
Psychopharmacology (Berl). 2013 Oct;229(4):591-601
pubmed: 23652588
Biochem Biophys Res Commun. 1995 Oct 4;215(1):89-97
pubmed: 7575630
Annu Rev Neurosci. 2011;34:105-30
pubmed: 21438686
Vitam Horm. 2009;81:191-205
pubmed: 19647113
Neuropharmacology. 2009 May-Jun;56(6-7):970-4
pubmed: 19371584
Pharmacol Biochem Behav. 1991 Nov;40(3):471-8
pubmed: 1666911
Psychopharmacology (Berl). 2009 Sep;205(4):613-24
pubmed: 19484221
Biol Psychiatry. 2011 Apr 1;69(7):633-41
pubmed: 20801430
Pharmacol Res. 2014 Aug;86:42-9
pubmed: 24704146